• 1
    Chan SL, Mo FK, Johnson PJ et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 2011; 26: 3407.
  • 2
    Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005; 7: 3541.
  • 3
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 10202.
  • 4
    Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 37890.
  • 5
    Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 2534.
  • 6
    Chan SL, Mo FK, Wong CS et al. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2011: doi: 10.1002/cncr.26726. [Epub ahead of print].
  • 7
    D'Avola D, Inarrairaegui M, Pardo F et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol 2011; 18: 196471.
  • 8
    Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol 2012; 27: 4527.
  • 9
    Wang JH, Changchien CS, Hu TH et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – survival analysis of 3892 patients. Eur J Cancer 2008; 44: 100006.
  • 10
    Chan LC, Chiu SK, Chan SL. Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. Hong Kong Med J 2011; 17: 1128.
  • 11
    Woo HY, Bae SH, Park JY et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010; 65: 37382.
  • 12
    Kim BK, Park JY, Choi HJ et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 65967.
  • 13
    Han KH, Kudo M, Ye SL et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011; 81 (Suppl. 1): 15864.
  • 14
    Poon D, Anderson BO, Chen LT et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 11118.
  • 15
    Jeong SW, Jang JY, Lee JE et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia–Pac J Clin Oncol 2012; 8: 16471.
  • 16
    Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. Asia–Pac J Clin Oncol 2012; 8: 15663.
  • 17
    Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia–Pac J Clin Oncol 2010; 6: 808.
  • 18
    Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 15328.
  • 19
    Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27: 44652.
  • 20
    Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012: doi: 10.1111/j.440-746.2012.07096.x. [Epub ahead of print].
  • 21
    Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2011; 42: 3408.
  • 22
    Cheng AL, Guan Z, Chen Z et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer 2012 [Cited 4 April 2012.] Available from URL .
  • 23
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 39607.
  • 24
    Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 211727.
  • 25
    Lencioni R, Llovet J, Han G et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012; 30: (Suppl. 4: Abstract LBA154.
  • 26
    Azad A, Chionh F, Cebon J. Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia-Pac J Clin Oncol 2009; 5: 7686.
  • 27
    Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep 2012; doi: 10.1007/s11912-012-0233-0. [Epub ahead of print].
  • 28
    Poggi G, Montagna B, Melchiorre F et al. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. Anticancer Res 2011; 31: 392733.
  • 29
    Johnson PJ, Kalayci C, Dobbs N et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991; 13: 1207.
  • 30
    Kalayci C, Johnson PJ, Raby N, Metivier EM, Williams R. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J Hepatol 1990; 11: 34953.